2019冠状病毒病背景下基于性别的疫苗反应 - Suppr

Suppr

超能文献

Sex-Based Vaccine Response in the Context of COVID-19.

作者信息

McCartney Patricia Robin

出版信息

J Obstet Gynecol Neonatal Nurs. 2020 Sep;49(5):405-408. doi: 10.1016/j.jogn.2020.08.001. Epub 2020 Aug 5.

DOI:10.1016/j.jogn.2020.08.001

PMID:32800743

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7405769/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c68/7405769/8be1ac6773e1/fx1_lrg.jpg

相似文献

Sex-Based Vaccine Response in the Context of COVID-19.

J Obstet Gynecol Neonatal Nurs. 2020 Sep;49(5):405-408. doi: 10.1016/j.jogn.2020.08.001. Epub 2020 Aug 5.

A vaccine is not too far for COVID-19.

J Infect Dev Ctries. 2020 May 31;14(5):450-453. doi: 10.3855/jidc.12744.

COVID-19 vaccine trials in Africa.

Lancet Respir Med. 2020 Nov;8(11):e79-e80. doi: 10.1016/S2213-2600(20)30401-X. Epub 2020 Sep 5.

The Russian vaccine for COVID-19.

Lancet Respir Med. 2020 Nov;8(11):e85-e86. doi: 10.1016/S2213-2600(20)30402-1. Epub 2020 Sep 5.

Vaccine wagers on coronavirus surface protein pay off.

Science. 2020 Nov 20;370(6519):894-895. doi: 10.1126/science.370.6519.894.

Exploit T cell Immunity for Rapid, Safe and Effective COVID-19 Vaccines.

Expert Rev Vaccines. 2020 Sep;19(9):781-784. doi: 10.1080/14760584.2020.1825946. Epub 2020 Oct 6.

COVID vaccine excitement builds as Moderna reports third positive result.

Nature. 2020 Nov;587(7834):337-338. doi: 10.1038/d41586-020-03248-7.

Covid-19 Vaccine Trials and Incarcerated People - The Ethics of Inclusion.

N Engl J Med. 2020 Nov 12;383(20):1897-1899. doi: 10.1056/NEJMp2025955. Epub 2020 Oct 21.

Rational Vaccine Design in the Time of COVID-19.

Cell Host Microbe. 2020 May 13;27(5):695-698. doi: 10.1016/j.chom.2020.04.022.

The Race to Develop a COVID-19 Vaccine.

Am J Nurs. 2020 Oct;120(10):14-15. doi: 10.1097/01.NAJ.0000718556.85319.00.

引用本文的文献

Comparative study of anti-SARS-CoV-2 receptor-binding domain total antibody titer before and after heterologous booster with mRNA-based COVID-19 vaccine.

Narra J. 2024 Dec;4(3):e788. doi: 10.52225/narra.v4i3.788. Epub 2024 Dec 20.

Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from Greece.

Vacunas. 2023 May 26. doi: 10.1016/j.vacun.2023.05.005.

Manifestations of adverse events post Sinovac vaccine immunization at Wirasakti Hospital, Kupang.

J Public Health Afr. 2023 Apr 19;14(4):1963. doi: 10.4081/jphia.2023.1963. eCollection 2023 Apr 30.

Sex-disaggregated effectiveness data reporting in COVID-19 vaccine research: a systematic review.

Commun Med (Lond). 2023 May 19;3(1):69. doi: 10.1038/s43856-023-00297-7.

The Course of COVID-19 among Unvaccinated Patients-Data from the National Hospital in Warsaw, Poland.

Vaccines (Basel). 2023 Mar 16;11(3):675. doi: 10.3390/vaccines11030675.

Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study.

Vaccines (Basel). 2023 Jan 22;11(2):247. doi: 10.3390/vaccines11020247.

A 1-year analysis of adverse events following COVID-19 vaccination in Lebanon: a retrospective study.

J Pharm Policy Pract. 2023 Feb 21;16(1):24. doi: 10.1186/s40545-023-00528-1.

Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection.

Front Immunol. 2023 Jan 13;13:1075423. doi: 10.3389/fimmu.2022.1075423. eCollection 2022.

A retrospective evaluation of side-effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID-19 vaccine among females in Eastern Province, Saudi Arabia.

Vaccine. 2022 Nov 22;40(49):7087-7096. doi: 10.1016/j.vaccine.2022.10.009. Epub 2022 Oct 17.

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.

PLoS One. 2022 Oct 17;17(10):e0268419. doi: 10.1371/journal.pone.0268419. eCollection 2022.

本文引用的文献

A review of criteria strictness in "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials".

Vaccine. 2023 Aug 31;41(38):5622-5629. doi: 10.1016/j.vaccine.2023.07.072. Epub 2023 Aug 1.

Encouraging results from phase 1/2 COVID-19 vaccine trials.

Lancet. 2020 Aug 15;396(10249):448-449. doi: 10.1016/S0140-6736(20)31611-1. Epub 2020 Jul 20.

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20.

An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.

N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14.

Biological sex impacts COVID-19 outcomes.

PLoS Pathog. 2020 Jun 22;16(6):e1008570. doi: 10.1371/journal.ppat.1008570. eCollection 2020 Jun.

Considering how biological sex impacts immune responses and COVID-19 outcomes.

Nat Rev Immunol. 2020 Jul;20(7):442-447. doi: 10.1038/s41577-020-0348-8. Epub 2020 Jun 11.

Aggregating data from COVID-19 trials.

Science. 2020 Jun 12;368(6496):1198-1199. doi: 10.1126/science.abc8993.

A strategic approach to COVID-19 vaccine R&D.

Science. 2020 May 29;368(6494):948-950. doi: 10.1126/science.abc5312. Epub 2020 May 11.

Clinical trials for COVID-19 should include sex as a variable.

J Clin Invest. 2020 Jul 1;130(7):3350-3352. doi: 10.1172/JCI139306.

Sex differences in vaccine-induced humoral immunity.

Semin Immunopathol. 2019 Mar;41(2):239-249. doi: 10.1007/s00281-018-0726-5. Epub 2018 Dec 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Sex-Based Vaccine Response in the Context of COVID-19.

J Obstet Gynecol Neonatal Nurs. 2020 Sep;49(5):405-408. doi: 10.1016/j.jogn.2020.08.001. Epub 2020 Aug 5.

A vaccine is not too far for COVID-19.

J Infect Dev Ctries. 2020 May 31;14(5):450-453. doi: 10.3855/jidc.12744.

COVID-19 vaccine trials in Africa.

Lancet Respir Med. 2020 Nov;8(11):e79-e80. doi: 10.1016/S2213-2600(20)30401-X. Epub 2020 Sep 5.

The Russian vaccine for COVID-19.

Lancet Respir Med. 2020 Nov;8(11):e85-e86. doi: 10.1016/S2213-2600(20)30402-1. Epub 2020 Sep 5.

Vaccine wagers on coronavirus surface protein pay off.

Science. 2020 Nov 20;370(6519):894-895. doi: 10.1126/science.370.6519.894.

Exploit T cell Immunity for Rapid, Safe and Effective COVID-19 Vaccines.

Expert Rev Vaccines. 2020 Sep;19(9):781-784. doi: 10.1080/14760584.2020.1825946. Epub 2020 Oct 6.

COVID vaccine excitement builds as Moderna reports third positive result.

Nature. 2020 Nov;587(7834):337-338. doi: 10.1038/d41586-020-03248-7.

Covid-19 Vaccine Trials and Incarcerated People - The Ethics of Inclusion.

N Engl J Med. 2020 Nov 12;383(20):1897-1899. doi: 10.1056/NEJMp2025955. Epub 2020 Oct 21.

Rational Vaccine Design in the Time of COVID-19.

Cell Host Microbe. 2020 May 13;27(5):695-698. doi: 10.1016/j.chom.2020.04.022.

The Race to Develop a COVID-19 Vaccine.

Am J Nurs. 2020 Oct;120(10):14-15. doi: 10.1097/01.NAJ.0000718556.85319.00.

引用本文的文献

Comparative study of anti-SARS-CoV-2 receptor-binding domain total antibody titer before and after heterologous booster with mRNA-based COVID-19 vaccine.

Narra J. 2024 Dec;4(3):e788. doi: 10.52225/narra.v4i3.788. Epub 2024 Dec 20.

Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from Greece.

Vacunas. 2023 May 26. doi: 10.1016/j.vacun.2023.05.005.

Manifestations of adverse events post Sinovac vaccine immunization at Wirasakti Hospital, Kupang.

J Public Health Afr. 2023 Apr 19;14(4):1963. doi: 10.4081/jphia.2023.1963. eCollection 2023 Apr 30.

Sex-disaggregated effectiveness data reporting in COVID-19 vaccine research: a systematic review.

Commun Med (Lond). 2023 May 19;3(1):69. doi: 10.1038/s43856-023-00297-7.

The Course of COVID-19 among Unvaccinated Patients-Data from the National Hospital in Warsaw, Poland.

Vaccines (Basel). 2023 Mar 16;11(3):675. doi: 10.3390/vaccines11030675.

Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study.

Vaccines (Basel). 2023 Jan 22;11(2):247. doi: 10.3390/vaccines11020247.

A 1-year analysis of adverse events following COVID-19 vaccination in Lebanon: a retrospective study.

J Pharm Policy Pract. 2023 Feb 21;16(1):24. doi: 10.1186/s40545-023-00528-1.

Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection.

Front Immunol. 2023 Jan 13;13:1075423. doi: 10.3389/fimmu.2022.1075423. eCollection 2022.

A retrospective evaluation of side-effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID-19 vaccine among females in Eastern Province, Saudi Arabia.

Vaccine. 2022 Nov 22;40(49):7087-7096. doi: 10.1016/j.vaccine.2022.10.009. Epub 2022 Oct 17.

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.

PLoS One. 2022 Oct 17;17(10):e0268419. doi: 10.1371/journal.pone.0268419. eCollection 2022.

本文引用的文献

A review of criteria strictness in "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials".

Vaccine. 2023 Aug 31;41(38):5622-5629. doi: 10.1016/j.vaccine.2023.07.072. Epub 2023 Aug 1.

Encouraging results from phase 1/2 COVID-19 vaccine trials.

Lancet. 2020 Aug 15;396(10249):448-449. doi: 10.1016/S0140-6736(20)31611-1. Epub 2020 Jul 20.

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20.

An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.

N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14.

Biological sex impacts COVID-19 outcomes.

PLoS Pathog. 2020 Jun 22;16(6):e1008570. doi: 10.1371/journal.ppat.1008570. eCollection 2020 Jun.

Considering how biological sex impacts immune responses and COVID-19 outcomes.

Nat Rev Immunol. 2020 Jul;20(7):442-447. doi: 10.1038/s41577-020-0348-8. Epub 2020 Jun 11.

Aggregating data from COVID-19 trials.

Science. 2020 Jun 12;368(6496):1198-1199. doi: 10.1126/science.abc8993.

A strategic approach to COVID-19 vaccine R&D.

Science. 2020 May 29;368(6494):948-950. doi: 10.1126/science.abc5312. Epub 2020 May 11.

Clinical trials for COVID-19 should include sex as a variable.

J Clin Invest. 2020 Jul 1;130(7):3350-3352. doi: 10.1172/JCI139306.

Sex differences in vaccine-induced humoral immunity.

Semin Immunopathol. 2019 Mar;41(2):239-249. doi: 10.1007/s00281-018-0726-5. Epub 2018 Dec 13.